Title |
Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study
|
---|---|
Published in |
Virology Journal, February 2013
|
DOI | 10.1186/1743-422x-10-57 |
Pubmed ID | |
Authors |
Luísa Hoffmann, Juliene Antonio Ramos, Elizabeth Valentin de Souza, Ana Lucia de Araújo Ramos, Cristiane Alves Villela-Nogueira, Turán Péter Ürményi, Amilcar Tanuri, Edson Rondinelli, Rosane Silva |
Abstract |
About sixty thousand new cases of Hepatitis C virus (HCV) infection are recorded in Brazil each year. These cases are currently treated with pegylated interferon (PEG-IFN) and ribavirin (RBV) with an overall success rate of 50%. New compounds for anti-HCV therapy targeted to the HCV NS3 protease are being developed and some already form the components of licensed therapies. Mapping NS3 protease resistance mutations to protease inhibitors or anti-viral drug candidates is important to direct anti-HCV drug treatment. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 37 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 6 | 16% |
Researcher | 5 | 14% |
Student > Master | 4 | 11% |
Student > Bachelor | 3 | 8% |
Professor | 3 | 8% |
Other | 9 | 24% |
Unknown | 7 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 27% |
Agricultural and Biological Sciences | 9 | 24% |
Biochemistry, Genetics and Molecular Biology | 4 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
Immunology and Microbiology | 1 | 3% |
Other | 2 | 5% |
Unknown | 9 | 24% |